Skip to main content

Table 2 Treatment outcome: studies conducted in malaria endemic countries with >10 patients and follow up data available

From: The hyper-reactive malarial splenomegaly: a systematic review of the literature

Study Country N patients Type of treatment Duration Follow up Outcome
Pryor 1967 [49] New Guinea 99 CLQ 1500 mg/3 days, then 300 mg/wk NR average 4.1 mths in hospital plus 6-23 mths out No change in spleen size, general benefit
Sagoe 1970 [57] Nigeria 43 PG 100 mg/day ≥6 mths 6 mths 32 improved 11 worsened
Bagshawe 1970 [13] Kenya 28 PG 100 mg/day 1 - 26 mths 1 -6 mths 16 improved 11 worsened 8 unchanged
Stuvier et al. 1971 [27] India 14 PQ 15 days, then CLQ 300 mg/wk 6-14 mths once/mths for ≥6 mths 11/14 spleen size ↓50%
Stuvier et al. 1974 [71] Uganda 41 CLQ 300 mg/wk or PG 100 mg/day NR 4- 20 mths all improved
Bryceson et al. 1976 [60] North Nigeria 30 PG 100 mg/day 3 - 12 mths 3 mths 12/13 improved (17 lost)
Fakunle and Greenwood 1980 [64] Nigeria 69 PG 100 mg/day 3 mths 10 wks 2 /40 died plus 8/29 defaulters
De Cock et al. 1986 [52] Kenya 38 PG 100 mg/day or CLQ 300 mg/wk NR NR 13/18 improved (20 lost)
Crane 1986 [2] Papua NG 148 CLQ 300 mg/wk lifelong 12-18 mths 146 improved (2 lost)
Gupta et al. 1987 [31] India 54 CLQ 300 mg, 1 or 2/wk 2 yrs 2 yrs 54 Improved
Mac Onuigbo and Mbah 1992 [76] Nigeria 39 PG 100 or 200 mg 2 - 12 mths 2 - 12 mths All improved (10 cured)
Manenti et al. 1994 [79] Tanzania 312 PMT 25 mg/wk 1 mths 3 mths 208 improved 104 unchanged
A-Elgayoum et al. 2011 [18] Sudan 54 Single short term treatment (various regimens) 1 d to 1 wk (often repeated) 15 –24 mths 36 improved 12 worsened 6 unchanged
Alkadarow et al. 2013 [69] Sudan 33 CLQ 300 mg/wk 3 mths 3 mths 14/21 improved (12 lost)
  1. (CLQ = chloroquine; PG = proguanil; PQ = primaquine; PMT = pyrimethamine; NR = not reported).